Business development executives on site at this year’s BIO International Convention in San Diego noted that while the total dollar value of deals announced so far in 2024 may not be as high as it was at mid-year in 2023, negotiations for new partnerships and M&A are keeping dealmakers busy.
Competitive Dealmaking Market Shifts To Smaller M&A, Partnering
Acquisition Numbers Rise, Values Fall In Q1
Dollars spent on biopharma M&A so far in 2024 may not be as high as in 2023, but dealmakers say deal volume is robust with many factors influencing the overall value of transactions this year.
